Research and production company Mikrokhim, traditionally specialized in the production of cardiological preparations, has started to develop the first domestic drug for the treatment of coronaviruses.
This was reported today by the company’s press service.
“In particular, the company’s scientific departments have started to develop a generic copy of the antiviral drug Avigan, also known by trade names such as Favipiravir and T-705. The original drug was developed in Japan in 2014, in 2015 it passed the third phase of clinical trials in the United States. At the same time, it was tested during an epidemic in Wuhan and approved for experimental use in Italy against COVID-19, “said the report.
The management of the company believes that in a relatively short period of time, Ukraine is able to create its own generic base of drugs which will not be inferior in terms of efficacy and safety to the original drugs used to treat coronavirus.
“It will take some time to recreate and confirm the bioequivalence of the Ukrainian drug COVID-19. But in the case of the production of medicines by national pharmaceutical companies, we can expect a more favorable resolution of the situation than with the option of supply by foreign companies, “said Igor Pogromsky, managing director of Mikrokhim.
See also: AMCU calls on pharmacies and pharmaceutical companies not to raise prices
“Mikrokhim plans to enter the home stretch – the release and first deliveries of the finished drug within six months, which is an unprecedented case for our country. However, the company team is ready to switch to an improved mode of operation during this difficult time for all of us, ”said Mikrokhim.
As reported, according to the Ministry of Health, in Ukraine on the morning of April 1, 669 laboratory-confirmed cases of COVID-19, of which 17 were fatal, 10 patients recovered. 120 new cases were recorded per day.
According to the materials: ukrinform.ru